The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!

Thomas Bernd Dschietzig; Giuseppe M.C. Rosano; Stefan D. Anker

doi:10.1002/ehf2.13170

The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!

Thomas Bernd Dschietzig, Giuseppe M.C. Rosano, Stefan D. Anker

IRCCS San Raffaele Pisana

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	3274-3277
Number of pages	4
Journal	ESC heart failure
Volume	7
Issue number	6
DOIs	https://doi.org/10.1002/ehf2.13170
Publication status	Published - Dec 2020

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1002/ehf2.13170

Cite this

@article{382a21aada7845ae8ab8d0e58239bc6e,

title = "The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!",

author = "Dschietzig, {Thomas Bernd} and Rosano, {Giuseppe M.C.} and Anker, {Stefan D.}",

note = "Funding Information: T.B.D. is CEO of Relaxera, a company developing relaxin‐2 for cardiovascular indications. S.D.A. reports receiving fees from Abbott, Bayer, Boehringer Ingelheim, Cardiac Dimension, Impulse Dynamics, Novartis, Occlutech, Servier, and Vifor Pharma and grant support from Abbott and Vifor Pharma (all unrelated to this paper). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = dec,

doi = "10.1002/ehf2.13170",

language = "English",

volume = "7",

pages = "3274--3277",

journal = "ESC heart failure",

issn = "2055-5822",

publisher = "Wiley Blackwell",

number = "6",

}

TY - JOUR

T1 - The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction

T2 - not the result of relaxin effects but of BNP action?!

AU - Dschietzig, Thomas Bernd

AU - Rosano, Giuseppe M.C.

AU - Anker, Stefan D.

N1 - Funding Information: T.B.D. is CEO of Relaxera, a company developing relaxin‐2 for cardiovascular indications. S.D.A. reports receiving fees from Abbott, Bayer, Boehringer Ingelheim, Cardiac Dimension, Impulse Dynamics, Novartis, Occlutech, Servier, and Vifor Pharma and grant support from Abbott and Vifor Pharma (all unrelated to this paper). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85097552124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097552124&partnerID=8YFLogxK

U2 - 10.1002/ehf2.13170

DO - 10.1002/ehf2.13170

M3 - Editorial

AN - SCOPUS:85097552124

VL - 7

SP - 3274

EP - 3277

JO - ESC heart failure

JF - ESC heart failure

SN - 2055-5822

IS - 6

ER -